Apimeds Pharmaceuticals US, Inc (APUS) Stock

Apimeds Pharmaceuticals US, Inc (APUS) is a Healthcare stock trading at $5.13 (as of 2026-08-21), with a market capitalization of $7.74M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient used to address inflammation and pain symptoms associated with osteoarthritis and multiple sclerosis. The company is based in Hopewell, New Jersey and is a subsidiary of Api Meds, Inc.

Understand Apimeds Pharmaceuticals US, Inc: how it makes money

Apimeds Pharmaceuticals US develops, manufactures, and commercializes Apitox, an active pharmaceutical ingredient for treating inflammation and pain symptoms in osteoarthritis and multiple sclerosis, and it makes money by selling Apitox.

The profit model is tightly linked to whether Apimeds can successfully develop and commercialize Apitox, because its business centers on selling a single active pharmaceutical ingredient for specific indications.

Business quality (Weak): Limited disclosure here, with no reported segment or operating KPI data, and the latest period shows revenue at 0.0B with a large negative operating margin.

Bull case

  • Single product focus on Apitox: Because Apimeds researches, develops, manufactures, commercializes, and sells Apitox, successful commercialization would directly impact its ability to generate sales.
  • Clear clinical stage therapeutic focus: Apitox is targeted for inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis, which defines a specific market opportunity.

Bear case

  • Clinical stage uncertainty: As a clinical stage biopharmaceutical company, future development and commercialization outcomes are uncertain.
  • Revenue and profitability look weak in the latest period shown: For the period ended 2026-03-31, revenue is shown as 0.0B and operating margin is negative.
  • Dependence on Apitox: With the business description centered on Apitox, setbacks affecting that product could have an outsized impact.
Valuation — source: SEC EDGAR (first-party)
Price$5.13
Market Cap$7.74M
Price / Book0.07
Price / Sales98.99
FCF Yield-220.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$107595.00
Net Margin-5577.5%
Return on Equity-54.6%
Debt / Equity0.00
Current Ratio0.51
Revenue Growth (YoY)3710.0%
EPS Growth (YoY)205.6%
Financial Health — source: SEC EDGAR
Altman Z-Score3.27 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderHemenway Trust Co LLC ($490296.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOVinod Menon
Employees2
CountryUS
IPO Date2025-05-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • CNS Pharmaceuticals, Inc. (CNSP)
  • Xenetic Biosciences, Inc. (XBIO)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Enveric Biosciences, Inc. (ENVB)
  • Processa Pharmaceuticals, Inc. (PCSA)
  • Cadrenal Therapeutics, Inc. Common Stock (CVKD)
  • PMGC Holdings Inc. (ELAB)
  • AEON Biopharma, Inc. (AEON)
APUS earnings history · APUS institutional & insider holders · APUS KPIs & operating metrics · APUS financials · APUS investor presentations & press releases · APUS SEC filings · APUS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.